2 active not recruiting, 1 enrolling by invitation. 3 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Enrolling by invitation 1 |
| Phase 3 | 2 | Active not recruiting 1, Enrolling by invitation 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow tividenofusp alfa: new trials by email Literature Review of tividenofusp alfa trials Research Report on tividenofusp alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 tividenofusp alfa - Mucopolysaccharidosis II | Phase 2 / Phase 3 | Enrolling by invitation | Denali Therapeutics Inc. | 99 | 2023-09-20 | 2026-10-27 |
| A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) tividenofusp alfa, idursulfase - Mucopolysaccharidosis II | Phase 2 / Phase 3 | Active not recruiting | Denali Therapeutics Inc. | 65 | 2022-07-21 | 2026-09-09 |
| A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome tividenofusp alfa - Mucopolysaccharidosis II | Phase 1 / Phase 2 | Active not recruiting | Denali Therapeutics Inc. | 47 | 2020-07-16 | 2025-08-07 |
Mucopolysaccharidosis II (3) · Sudden Infant Death (3)
Canada (3) · Netherlands (3) · United Kingdom (3) · United States (3) · Argentina (2) · Belgium (2) · Brazil (2) · Czechia (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · Sweden (2) · Turkey (Türkiye) (2)
Jose Alcantara Rodriguez, PharmD (1) · Sam Lu, MD (1)
2023 (2), 2019 (1)